Generics Bulletin Editor’s Picks For Q2 2022
Highlights Across The Off-Patent Sector From April To June 2022
Looking back over the second quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from April to June that include multiple first generic and biosimilar launches, some noteworthy executive moves, further preparation for biosimilar competition to Humira in the US, and a major European industry conference.
